Blockade of HVEM for Prostate Cancer Immunotherapy in Humanized Mice

Blockade of HVEM for Prostate Cancer Immunotherapy in Humanized Mice

The herpes virus entry mediator (HVEM) delivers a negative signal to T cells mainly through the B and T lymphocyte attenuator (BTLA) molecule. Thus, HVEM/BTLA may represent a novel immune checkpoint during an anti-tumor immune response. However, a formal demonstration that HVEM can represent a targe...

Full description

Bibliographic Details
Main Authors:	Nicolas Aubert, Simon Brunel, Daniel Olive, Gilles Marodon
Format:	Article
Language:	English
Published:	MDPI AG 2021-06-01
Series:	Cancers
Subjects:	immune checkpoint HVEM BTLA monoclonal antibody cancer immunotherapy humanized mice
Online Access:	https://www.mdpi.com/2072-6694/13/12/3009

Similar Items

Beyond the anti-PD-1/PD-L1 era: promising role of the BTLA/HVEM axis as a future target for cancer immunotherapy
by: Christian Sordo-Bahamonde, et al.
Published: (2023-08-01)

BTLA-derived peptides as inhibitors of BTLA/HVEM complex formation – design, synthesis and biological evaluation
by: Katarzyna Kuncewicz, et al.
Published: (2023-09-01)

Lymphocyte HVEM/BTLA co-expression after critical illness demonstrates severity indiscriminate upregulation, impacting critical illness-induced immunosuppression
by: Michelle E. Wakeley, et al.
Published: (2023-05-01)

Attenuation of the BTLA/HVEM Regulatory Network in the Circulation in Primary Sjögren’s Syndrome
by: Annabelle Small, et al.
Published: (2022-01-01)

The BTLA–HVEM–CD5 Immunoregulatory Axis–An Instructive Mechanism Governing pTreg Cell Differentiation
by: Jessica Bourque, et al.
Published: (2019-05-01)

The Role of the Inhibitory Ligand HVEM and Its Receptors CD160 and BTLA in the Regulation of Anti-retroviral T Cell Responses
by: Paul David, et al.
Published: (2022-03-01)

BTLA inhibition has a dominant role in the cis-complex of BTLA and HVEM
by: Claire Battin, et al.
Published: (2022-08-01)

BTLA/HVEM Axis Induces NK Cell Immunosuppression and Poor Outcome in Chronic Lymphocytic Leukemia
by: Christian Sordo-Bahamonde, et al.
Published: (2021-04-01)

Virtual Evolution of HVEM Segment for Checkpoint Inhibitor Discovery
by: Mingjia Yu, et al.
Published: (2021-06-01)

HVEM Promotes the Osteogenesis of allo-MSCs by Inhibiting the Secretion of IL-17 and IFN-γ in Vγ4T Cells
by: Lei He, et al.
Published: (2021-06-01)

Tumor Cell-Intrinsic BTLA Receptor Inhibits the Proliferation of Tumor Cells via ERK1/2
by: Tian-You Cheng, et al.
Published: (2022-12-01)

Herpesvirus Entry Mediator Binding Partners Mediate Immunopathogenesis of Ocular Herpes Simplex Virus 1 Infection
by: Seo J. Park, et al.
Published: (2020-06-01)

High BTLA Expression Likely Contributes to Contraction of the Regulatory T Cell Subset in Lupus Disease
by: Lucie Aubergeon, et al.
Published: (2021-11-01)

CANCER IMMUNOTHERAPY BASED ON THE BLOCKADE OF IMMUNE CHECKPOINTS
by: A. V. Bogolyubova, et al.
Published: (2015-10-01)

Targeting the Human T-Cell Inducible COStimulator Molecule with a Monoclonal Antibody Prevents Graft-vs-Host Disease and Preserves Graft vs Leukemia in a Xenograft Murine Model
by: Aude Burlion, et al.
Published: (2017-06-01)

BTLA biology in cancer: from bench discoveries to clinical potentials
by: Anna Andrzejczak, et al.
Published: (2024-01-01)

BTLA blockade enhances Cancer therapy by inhibiting IL-6/IL-10-induced CD19high B lymphocytes
by: Yu-Li Chen, et al.
Published: (2019-11-01)

Monoclonal Antibodies in Dermatooncology—State of the Art and Future Perspectives
by: Malgorzata Bobrowicz, et al.
Published: (2019-09-01)

Current status of cancer immunotherapy
by: Kono K
Published: (2014-04-01)

Genetic deletion of HVEM in a leukemia B cell line promotes a preferential increase of PD-1- stem cell-like T cells over PD-1+ T cells curbing tumor progression
by: Maria-Luisa del Rio, et al.
Published: (2023-03-01)

The Evolution of Cancer Immunotherapy
by: Meshaal Khan, et al.
Published: (2021-06-01)

Current Advancements and Future Perspectives of Immunotherapy in Breast Cancer Treatment
by: Maria Vasileiou, et al.
Published: (2023-05-01)

Not All Immune Checkpoints Are Created Equal
by: Annika De Sousa Linhares, et al.
Published: (2018-08-01)

Mechanisms of action of monoclonal antibodies in oncology integrated in IMGT/mAb-DB
by: Taciana Manso, et al.
Published: (2023-05-01)

A new emerging target in cancer immunotherapy: Galectin-9 (LGALS9)
by: Yan Lv, et al.
Published: (2023-11-01)

Friend or Foe: Prognostic and Immunotherapy Roles of BTLA in Colorectal Cancer
by: Jingjing Song, et al.
Published: (2020-07-01)

HVEM/HIF-1α promoted proliferation and inhibited apoptosis of ovarian cancer cells under hypoxic microenvironment conditions
by: Liyan Duan, et al.
Published: (2020-04-01)

Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy
by: Laura Boyero, et al.
Published: (2020-12-01)

The Immunotherapy for Colorectal Cancer, Lung Cancer and Pancreatic Cancer
by: Shiu-Jau Chen, et al.
Published: (2021-11-01)

Recombinant antibodies for immunotherapy /
by: Little, Melvyn
Published: (2009)

HVEM and CD160: Regulators of Immunopathology During Malaria Blood-Stage
by: Franziska Muscate, et al.
Published: (2018-11-01)

Targeting Negative and Positive Immune Checkpoints with Monoclonal Antibodies in Therapy of Cancer
by: Katsiaryna Marhelava, et al.
Published: (2019-11-01)

Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous Melanoma
by: Mariana Aris, et al.
Published: (2017-08-01)

Harnessing Tumor Necrosis Factor Alpha to Achieve Effective Cancer Immunotherapy
by: María Florencia Mercogliano, et al.
Published: (2021-02-01)

Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of Immunotherapy
by: Giorgio Parmiani, et al.
Published: (2015-05-01)

Characterization of a novel potency endpoint for the evaluation of immune checkpoint blockade in humanized mice
by: Alba Matas-Céspedes, et al.
Published: (2023-03-01)

Editorial: Immunotherapy in Multiple Myeloma
by: Nicola Giuliani, et al.
Published: (2019-08-01)

A new alternative cancer treatment modality: Immunotherapy
by: Vidhya Kalanjiam, et al.
Published: (2015-01-01)

The soluble amino-terminal region of HVEM mediates efficient herpes simplex virus type 1 infection of gD receptor-negative cells
by: Baek Hyunjung, et al.
Published: (2012-01-01)

Microbial synthesis of Prussian blue for potentiating checkpoint blockade immunotherapy
by: Wang, Dongdong, et al.
Published: (2023)